Jun 4 |
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
May 30 |
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
|
May 22 |
Earnings Release: Here's Why Analysts Cut Their Compugen Ltd. (NASDAQ:CGEN) Price Target To US$5.00
|
May 20 |
Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript
|
May 20 |
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
|
May 20 |
Compugen GAAP EPS of -$0.08 beats by $0.03, revenue of $2.56M beats by $1.35M
|
May 20 |
Compugen Reports First Quarter 2024 Results
|
May 17 |
Compugen Q1 2024 Earnings Preview
|
May 16 |
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
|
May 15 |
Compugen names David Silberman as finance chief
|